Blastoid mantle cell lymphoma occurring in a patient in complete remission of chronic myelogenous leukemia.
The development of a de novo lymphoma in patients affected by chronic myelogenous leukemia (CML) is a rare event. The introduction of new molecular cytogenetic techniques, such as fluorescence in situ hybridization (FISH), allows a correct differential diagnosis between lymphoid blastic crisis and a blastoid variant of mantle cell lymphoma (MCL), which shows an aggressive behavior and some molecular characteristics detectable by cytogenetics and immunohistochemistry. We report a case of a blastoid variant of MCL that developed in a patient with CML who achieved complete cytogenetic and molecular response to imatinib mesylate treatment.
Garzia
M
M
Dipartimento di Diagnostica Morfologica, Microbiologica, Molecolare e delle Malattie del Sangue, Catholic University of Sacred Heart, Rome, Italy.
Sora
F
F
Teofili
L
L
Di Mario
A
A
Voso
M T
MT
Rumi
C
C
La Rocca
L M
LM
Sica
S
S
Zini
G
G
D000970:Antineoplastic Agents / Q000627:therapeutic use; D001549:Benzamides; D017809:Fatal Outcome; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000150:complications* / Q000188:drug therapy; D020522:Lymphoma, Mantle-Cell / Q000150:complications* / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use; D012074:Remission Induction
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate